HomeCompareOILX vs ABBV

OILX vs ABBV: Dividend Comparison 2026

OILX yields 34.66% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OILX wins by $70.3K in total portfolio value
10 years
OILX
OILX
● Live price
34.66%
Share price
$5.77
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$172.6K
Annual income
$25,855.68
Full OILX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OILX vs ABBV

📍 OILX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOILXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OILX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OILX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OILX
Annual income on $10K today (after 15% tax)
$2,946.27/yr
After 10yr DRIP, annual income (after tax)
$21,977.33/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OILX beats the other by $921.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OILX + ABBV for your $10,000?

OILX: 50%ABBV: 50%
100% ABBV50/50100% OILX
Portfolio after 10yr
$137.5K
Annual income
$25,313.72/yr
Blended yield
18.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OILX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OILX buys
0
ABBV buys
0
No recent congressional trades found for OILX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOILXABBV
Forward yield34.66%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$172.6K$102.3K
Annual income after 10y$25,855.68$24,771.77
Total dividends collected$124.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OILX vs ABBV ($10,000, DRIP)

YearOILX PortfolioOILX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,166$3,466.20$11,550$430.00+$2.6KOILX
2$19,747$4,589.06$13,472$627.96+$6.3KOILX
3$27,108$5,978.41$15,906$926.08+$11.2KOILX
4$36,675$7,669.97$19,071$1,382.55+$17.6KOILX
5$48,941$9,698.18$23,302$2,095.81+$25.6KOILX
6$64,461$12,094.95$29,150$3,237.93+$35.3KOILX
7$83,862$14,888.49$37,536$5,121.41+$46.3KOILX
8$107,835$18,102.29$50,079$8,338.38+$57.8KOILX
9$137,137$21,754.18$69,753$14,065.80+$67.4KOILX
10$172,593$25,855.68$102,337$24,771.77+$70.3KOILX

OILX vs ABBV: Complete Analysis 2026

OILXStock

The investment seeks to provide exposure to potential price appreciation in the S&P GSCI Crude Oil Total Return Index (the “index”). The index is a sub-index of the S&P GSCI commodity index (“S&P GSCI”) and measures the returns from the West Texas Intermediate crude oil futures contract traded on the New York Mercantile Exchange.

Full OILX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OILX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OILX vs SCHDOILX vs JEPIOILX vs OOILX vs KOOILX vs MAINOILX vs JNJOILX vs MRKOILX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.